{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:47:30Z","timestamp":1789433250280,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1124\/dmd.108.021725","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T20:44:35Z","timestamp":1212007475000},"page":"1770-1779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Covalent Binding and Tissue Distribution\/Retention Assessment of Drugs Associated with Idiosyncratic Drug Toxicity"],"prefix":"10.1016","volume":"36","author":[{"given":"Hideo","family":"Takakusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Masumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yukinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.108.021725_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/tx960017o","article-title":"Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma","volume":"9","author":"Bailey","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/tx00004a001","article-title":"Metabolic activation of valproic acid and drug-mediated hepatotoxicity: role of the terminal olefin, 2-n-propyl-4-pentenoic acid","volume":"1","author":"Baillie","year":"1988","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/bms.1200220602","article-title":"Mass spectrometry in the analysis of glutathione conjugates","volume":"22","author":"Baillie","year":"1993","journal-title":"Biol Mass Spectrom"},{"key":"10.1124\/dmd.108.021725_bib4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/0006-2952(89)90184-6","article-title":"Drug-protein conjugates: XVIII. Detection of antibodies towards the antimalarial amodiaquinee and its quinone imine metabolite in man and the rat","volume":"38","author":"Christie","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.108.021725_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0090-9556(24)15168-9","article-title":"Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation","volume":"28","author":"Cuttle","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.021725_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/tx034170b","article-title":"Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development","volume":"17","author":"Evans","year":"2004","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1021\/tx0496791","article-title":"Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites","volume":"18","author":"Gan","year":"2005","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0026-895X(24)13269-5","article-title":"A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.108.021725_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1054\/mehy.1998.0734","article-title":"Drugs that induce neutropenia\/agranulocytosis may target specific components of the stromal cell extracellular matrix","volume":"53","author":"Guest","year":"1999","journal-title":"Med Hypotheses"},{"key":"10.1124\/dmd.108.021725_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1389200054021799","article-title":"A comprehensive listing of bioactivation pathways of organic functional groups","volume":"6","author":"Kalgutkar","year":"2005","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.108.021725_bib11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1124\/dmd.107.014860","article-title":"Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes","volume":"35","author":"Kang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.021725_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.108.021725_bib13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/tx050092b","article-title":"Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha, beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme","volume":"18","author":"Kassahun","year":"2005","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0026-895X(25)10831-6","article-title":"Mechanisms of activation of phenacetin to reactive metabolites by cytochrome P-450: a theoretical study involving radical intermediates","volume":"37","author":"Koymans","year":"1990","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.108.021725_bib15","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/0006-2952(83)90470-7","article-title":"Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats","volume":"32","author":"Larrey","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.108.021725_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-2797(02)00051-0","article-title":"A review of the common properties of drugs with idiosyncratic hepatotoxicity and the \u201cmultiple determinant hypothesis\u201d for the manifestation of idiosyncratic drug toxicity","volume":"142","author":"Li","year":"2002","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.108.021725_bib17","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1021\/tx7001228","article-title":"Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate","volume":"20","author":"McDonald","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-2952(93)90342-T","article-title":"An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro: studies with human and rat liver microsomes","volume":"46","author":"Madden","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.108.021725_bib19","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/0006-2952(87)90130-4","article-title":"Autoxidative formation of a chemically reactive intermediate from amodiaquinee, a myelotoxin and hepatotoxin in man","volume":"36","author":"Maggs","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.108.021725_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1021\/tx060234h","article-title":"Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans","volume":"20","author":"Masubuchi","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0022-3565(25)21182-X","article-title":"Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate","volume":"279","author":"Masubuchi","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.021725_bib22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/mol.62.3.628","article-title":"Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation","volume":"62","author":"Naisbitt","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.108.021725_bib23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0022-3565(25)24566-9","article-title":"Metabolism and bioactivation of clozapine by human liver in vitro","volume":"272","author":"Pirmohamed","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.021725_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.pharmtox.37.1.91","article-title":"Protein targets of xenobiotic reactive intermediates","volume":"37","author":"Pumford","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.108.021725_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00130832-200308000-00001","article-title":"The danger hypothesis applied to idiosyncratic drug reactions","volume":"3","author":"S\u00e9guin","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1124\/dmd.108.021725_bib26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(25)20618-8","article-title":"Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide","volume":"232","author":"Uetrecht","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.021725_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: past, present, and future","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1021\/tx00044a007","article-title":"Oxidation of aminopyrine by hypochlorite to a reactive dictation: possible implications for aminopyrine-induced agranulocytosis","volume":"8","author":"Uetrecht","year":"1995","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.021725_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10408440590935620","article-title":"Role of metabolism in drug-induced idiosyncratic hepatotoxicity","volume":"35","author":"Walgren","year":"2005","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/dmd.108.021725_bib30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0024-3205(00)00981-4","article-title":"Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac","volume":"68","author":"Wang","year":"2001","journal-title":"Life Sci"},{"key":"10.1124\/dmd.108.021725_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1081\/DMR-200028812","article-title":"Drug bioactivation, covalent binding to target proteins and toxicity relevance","volume":"37","author":"Zhou","year":"2005","journal-title":"Drug Metab Rev"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624017768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624017768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.108.021725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:28:38Z","timestamp":1739878118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624017768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0090955624017768"],"URL":"https:\/\/doi.org\/10.1124\/dmd.108.021725","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1119568.575781","asserted-by":"object"}]},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Covalent Binding and Tissue Distribution\/Retention Assessment of Drugs Associated with Idiosyncratic Drug Toxicity","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.108.021725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2008 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}